Studies have shown that RSAD2 inhibits the proliferation and metastasis of cholangiocarcinoma (CCA) cells, suggesting that it influences tumor progression through the regulation of energy metabolism [107]. Here, RSAD2 is linked to cholangiocarcinoma.